Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.
about
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsMaximising the potential of AKT inhibitors as anti-cancer treatmentsInhibition of Human Lung Cancer Cell Proliferation and Survival by Post-Exercise Serum Is Associated with the Inhibition of Akt, mTOR, p70 S6K, and Erk1/2.Recent Advances in Uterine Fibroid Etiology.MDM2 inhibition rescues neurogenic and cognitive deficits in a mouse model of fragile X syndromeMitomycin C treatment induces resistance and enhanced migration via phosphorylated Akt in aggressive lung cancer cells.Cell type- and density-dependent effect of 1 T static magnetic field on cell proliferation.Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression.Targeting leiomyomas with all-trans-retinoic acid at phosphoinositide 3-kinase pathway suppression: Effective roles of β-catenin and of signaling interactions.AKT in cancer: new molecular insights and advances in drug development.New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer.Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non-Small Cell Lung Cancer with Activating Mutations of EGFR.Akt1 Stimulates Homologous Recombination Repair of DNA Double-Strand Breaks in a Rad51-Dependent Manner.Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.A-674563, a putative AKT1 inhibitor that also suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206.
P2860
Q26744339-AA300DA0-C496-459E-A4BA-34080B467AE9Q28072254-576A3F24-F462-45E7-B27A-9135EF159FD5Q33737286-48BD3DE3-AD4C-4B9A-9C95-207B6064CCE6Q33852886-6A4F5AB9-DF65-41E9-B064-133EB261668EQ37198789-7FF1061F-DD6B-413A-A57F-19CCC4FCAC8EQ37694878-29E5A397-6234-4FE8-85C6-D6F221D3E158Q37706560-D0CF5A1E-8622-4EC9-AD9E-DAC6CD304989Q37717138-0FA8D0F6-00CC-460F-B6D7-FB98BB57ADC3Q38761092-95E8B8CA-9B3C-4D5D-9ED3-95EF57C5F073Q38846044-B6616D40-0FC1-4AF2-9EC3-E6149EC1B11CQ39007500-44A2DFF1-E9E8-4618-9114-0E4137557F8DQ41606248-B7778BDC-0DF4-4F9B-BF8F-B948E346CC4CQ42382909-C8042E59-F725-4333-A0CA-A6E009DC415BQ42385508-05CDC886-0614-4697-ABF0-B337355A9F06Q47383621-8A77BA97-C4A8-45B8-A023-2B3CC16EBF64Q50345931-371C584F-B097-4AF4-A76D-EF595B8D82D9Q52731012-2E520549-4239-4C55-863D-454A66EAF719
P2860
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Phase II Study of the AKT Inhi ...... ously Progressed on Erlotinib.
@ast
Phase II Study of the AKT Inhi ...... ously Progressed on Erlotinib.
@en
type
label
Phase II Study of the AKT Inhi ...... ously Progressed on Erlotinib.
@ast
Phase II Study of the AKT Inhi ...... ously Progressed on Erlotinib.
@en
prefLabel
Phase II Study of the AKT Inhi ...... ously Progressed on Erlotinib.
@ast
Phase II Study of the AKT Inhi ...... ously Progressed on Erlotinib.
@en
P2093
P2860
P50
P1476
Phase II Study of the AKT Inhi ...... ously Progressed on Erlotinib.
@en
P2093
Barbara Gitlitz
Jeff Longmate
Mariana Koczywas
Mark A Socinski
Philip C Mack
Primo N Lara
Tianhong Li
P2860
P304
P356
10.1158/1078-0432.CCR-14-3281
P407
P577
2015-06-23T00:00:00Z